LatticeFlow AI Sets a New Standard for AI Governance With Evidence-Based Technical Assessments
17.9.2025 10:51:00 CEST | Business Wire | Press Release
LatticeFlow AI, the Swiss deep-tech company advancing trustworthy and compliant AI, today announced the Early Access Program for AI GO!, the first platform that enables AI Governance Operations through deep technical assessments. With this, LatticeFlow AI sets a new standard for AI governance and compliance, enabling organizations to accelerate their AI advantage.
Traditional Governance, Risk and Compliance (GRC) systems, based on checklists, are insufficient to govern complex and rapidly evolving AI systems. LatticeFlow AI GO! provides rigorous, evidence-based assessments that uncover AI risks, generate audit-ready insights, and empower confident decision-making. The platform equips AI risk and compliance teams with the visibility and confidence they need to harness the full potential of GenAI applications, chatbots, and the latest LLMs.
“The only way AI governance can work and scale is when it’s grounded in technical evidence,” said Petar Tsankov, CEO and Co-Founder of LatticeFlow AI. “With AI GO!, enterprises gain the deep insights they need to manage AI risks, prove compliance, and accelerate innovation with confidence.”
Building on its leadership as co-creator of COMPL-AI (the first framework to assess GenAI models against the EU AI Act) and grounded in Swiss precision and scientific rigor, LatticeFlow AI sets a new standard for doing AI governance right. The company transforms complex AI systems into transparent, auditable, and trustworthy insights enterprises can rely on for any framework, standard or regulation, such as NIST, ISO, and the EU AI Act.
More information and demos of LatticeFlow AI GO! are available on this link.
Getting AI Governance Right Through Evidence and Trust
With AI GO!, LatticeFlow AI enables organizations to get AI governance right by combining rigorous technical assessments with the automation required to apply consistent oversight across departments and use cases.
Given its AI-first governance approach, the new platform allows teams to leverage out-of-the box AI risk frameworks, such as the EU AI Act, or add their own, custom AI risk frameworks, ensuring AI governance aligns with business needs.
In addition, LatticeFlow AI GO! is extensible across modalities and applications, from GenAI, LLMs, chatbots, to Computer Vision and Tabular models, providing a unified way to evaluate performance, safety, and compliance for any AI system.
Finally, the new platform supports a wide range of critical use cases, validating GenAI applications and chatbots, screening LLMs, assessing third-party AI risks, and ensuring compliance with regulations, such as the EU AI Act.
Advancing Evidence-Based EU AI Act Compliance
Building on its role as co-creator of COMPL-AI, the first framework to map EU AI Act principles to concrete technical controls, LatticeFlow AI is at the forefront of advancing evidence-based compliance. Most recently, the company delivered the first EU AI Act compliance-centered analysis of the Swiss LLM Apertus, which became the first large AI model compliant with the EU AI Act, further demonstrating its ability to translate regulatory principles into transparent, auditable technical assessments enterprises can rely on.
“The EU AI Act is a turning point for the industry,” added Dr. Tsankov. “It demands concrete technical evidence that AI systems are safe and trustworthy. With AI GO!, we help enterprises meet compliance head-on while continuing to drive innovation and value.”
Broad Industry Support
LatticeFlow AI’s industry leadership was recently highlighted at Trustworthy AI in Practice, a flagship event co-hosted with ETH Zurich last September 9th. The event underscored LatticeFlow AI’s deep scientific roots and its unique ability to convey the full AI ecosystem.
The event was a resounding success, uniting thought leaders from academia, industry, big tech, and enterprises to advance the discussion on making trustworthy AI a reality.
A key takeaway from the event was the pressing need for AI governance operations. Adrian Ott, Chief AI Officer at EY Switzerland, highlighted: “For successful AI transformation in businesses, it's crucial that AI innovation and risk management work in tandem rather than operating in opposition.”
Dr. Matthias Bossardt, Partner and Head of Cyber & Digital Risk at KPMG Switzerland, added: “To benefit from AI at scale, organizations must establish robust AI governance processes that enable efficient risk and performance monitoring.”
From the research and innovation view, Dr. Imanol Schlag, Technical Lead of the recently launched Swiss LLM Apertus, stressed: “The Swiss AI Initiative proves that large-scale efforts don't have to choose between capability and transparency.”
Finally, from a technology perspective, Dr. Naya Giannakopoulou, Senior Technical Architect at Microsoft Innovation Hub, remarked: “The future of enterprise-scale AI lies in guardrails that turn governance into an accelerator, not a blocker.”
Together, these perspectives reflect a shared vision: advancing AI governance through deep technical assessments that deliver trust, compliance, and innovation at scale.
About LatticeFlow AI
LatticeFlow AI sets a new standard in AI governance with deep technical assessments that enable evidence-based decisions and empower enterprises to accelerate their AI advantage.
As the creator of COMPL-AI, the world’s first EU AI Act framework for Generative AI developed with ETH Zurich and INSAIT, the company combines Swiss precision with scientific rigor to scale AI governance built on evidence and trust.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250917686559/en/
Contacts
Gloria Fernandez, Marketing Director, LatticeFlow AI - media@latticeflow.ai
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom